Sarcopenia, the age-related loss of muscle mass and function, imposes a dramatic burden on individuals and society. The development of preventive and therapeutic strategies against sarcopenia is therefore perceived as an urgent need by health professionals and has instigated intensive research on the pathophysiology of this syndrome. The pathogenesis of sarcopenia is multifaceted and encompasses lifestyle habits, systemic factors (e.g., chronic inflammation and hormonal alterations), local environment perturbations (e.g., vascular dysfunction), and intramuscular specific processes. In this scenario, derangements in skeletal myocyte mitochondrial function are recognized as major factors contributing to the age-dependent muscle degeneration. The presentation will summarize prominent findings and controversial issues on the contribution of specific mitochondrial processes – including oxidative stress, quality control mechanisms and apoptotic signalling – on the development of sarcopenia. Methodological and safety considerations for the design of clinical trials targeting mitochondrial dysfunction to treat sarcopenia will be discussed. Special emphasis will be placed on the importance of monitoring the effects of an intervention on muscle mitochondrial function and identifying the optimal target population for the trial.
Marzetti, E., Targeting mitochondrial dysfunction to treat sarcopenia: Opportunities and challenges, Abstract de <<11th Congress of the European Union Geriatric Medicine Society (EUGMS)>>, (Rotterdam, The Netherlands, 17-19 September 2014 ), <<EUROPEAN GERIATRIC MEDICINE>>, 2014; 6 (1): 95-95. 10.1016/j.eurger.2014.06.012 [https://hdl.handle.net/10807/243142]
Targeting mitochondrial dysfunction to treat sarcopenia: Opportunities and challenges
Marzetti, Emanuele
2015
Abstract
Sarcopenia, the age-related loss of muscle mass and function, imposes a dramatic burden on individuals and society. The development of preventive and therapeutic strategies against sarcopenia is therefore perceived as an urgent need by health professionals and has instigated intensive research on the pathophysiology of this syndrome. The pathogenesis of sarcopenia is multifaceted and encompasses lifestyle habits, systemic factors (e.g., chronic inflammation and hormonal alterations), local environment perturbations (e.g., vascular dysfunction), and intramuscular specific processes. In this scenario, derangements in skeletal myocyte mitochondrial function are recognized as major factors contributing to the age-dependent muscle degeneration. The presentation will summarize prominent findings and controversial issues on the contribution of specific mitochondrial processes – including oxidative stress, quality control mechanisms and apoptotic signalling – on the development of sarcopenia. Methodological and safety considerations for the design of clinical trials targeting mitochondrial dysfunction to treat sarcopenia will be discussed. Special emphasis will be placed on the importance of monitoring the effects of an intervention on muscle mitochondrial function and identifying the optimal target population for the trial.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.